GlassScriptPhysician profile
Michael Robert Schoech
NPI 1124237086
$57,931.29
in general payments reported to CMS, 2019-2025
8 companies · $41K in 2025
The $41K reported for 2025 was more than what 90% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,079 · 2020: $1,437 · 2021: $500 · 2024: $7,850 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Honoraria: $6,045 · Travel and Lodging: $2,525 · Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,057.50 |
| Honoraria | $6,045.00 |
| Travel and Lodging | $2,524.71 |
| Food and Beverage | $2,287.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $48,541.66 | 2024-2025 | Rezdiffra, Resmetirom |
| Alnylam Pharmaceuticals INC. | $4,170.91 | 2019 | |
| Abbvie INC. | $2,793.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,500.00 | 2020-2021 | |
| Saol Therapeutics INC. | $437.00 | 2020 | |
| Gilead Sciences, INC. | $189.39 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $174.04 | 2025 | Terlivaz |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schoech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.